Completed PHASE2 INTERVENTIONAL 1-arm NCT01137916

Study to Evaluate Imatinib in Desmoid Tumors

Phase II Study to Evaluate Glivec (Imatinib Mesylate) to Induce Progression Arrest in Aggressive Fibromatosis / Desmoid Tumors Not Amenable to Surgical Resection With R0 Intent or Accompanied by Unacceptable Function Loss

Sponsor: Heidelberg University

Conditions Aggressive Fibromatosis Desmoid Tumor

Interventions Imatinib

Updated 6 times since 2017 Last updated: May 2, 2017 Started: Jun 30, 2010 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Aggressive Fibromatosis and Desmoid Tumor, this trial is completed. The trial is conducted by Heidelberg University and has accumulated 6 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Heidelberg University
Novartis

Data source: Heidelberg University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mannheim, Germany